Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,499 JPY | -0.24% | -0.64% | -0.73% |
2023 | Harris Associates says cautious on Japan, all in on Europe | RE |
2023 | Consolidation to boost value of Japan's still fragmented drugstore sector - Orbis | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The stock, which is currently worth 2024 to 0.59 times its sales, is clearly overvalued in comparison with peers.
- The opinion of analysts covering the stock has improved over the past four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company does not generate enough profits, which is an alarming weak point.
- The company is highly valued given the cash flows generated by its activity.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.73% | 3.44B | D- | ||
-23.44% | 3.15B | D | ||
+7.98% | 2.76B | - | ||
+11.98% | 2.71B | C+ | ||
-9.90% | 1.79B | - | ||
+11.26% | 1.43B | - | - | |
-20.03% | 974M | - | ||
-37.98% | 710M | - | - | |
-0.53% | 454M | - | D+ | |
+5.58% | 409M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 9989 Stock
- Ratings Sundrug Co.,Ltd.